Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In this review, we outline the pathophysiology of severe asthma and discuss the role of anti-interleukin (IL)-5 inhibitors for the treatment of asthma. Anti-IL-5 treatments have shown efficacy in reducing the rate of severe asthma attacks in eosinophilic asthma. We review the history of the development of these agents, lessons learnt about severe asthma along the way and key clinical trials supporting efficacy of the three anti-IL-5 treatments that are clinically available or undergoing clinical trials in asthma.

Original publication

DOI

10.1007/s40259-017-0215-8

Type

Journal article

Journal

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Publication Date

04/2017

Volume

31

Pages

93 - 103

Addresses

Nuffield Department of Medicine, University of Oxford, NDM Research Building, Old Road Campus, Oxford, OX3 7FZ, UK.

Keywords

Eosinophils, Humans, Asthma, Anti-Asthmatic Agents, Interleukin-5, Receptors, Interleukin-5, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized